rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Artelo Biosciences, Inc.

ARTL · Nasdaq

Health CareBiotechnologyNot moving yet

ARTL stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 85.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
10 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders10+0 on the quarter
New · exited5 · 5
Reported value$132K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCadded · filed 14 Aug 202666,341$74K+53,262+407.2%
GEODE CAPITAL MANAGEMENT, LLCnew · filed 12 Aug 202613,864$16K+13,864
StoneX Group Inc.new · filed 12 Aug 202612,400$15K+12,400
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202610,129$11K00.0%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20268,435$9,447+5,609+198.5%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20263,139$3,51600.0%
UBS Group AGnew · filed 13 Aug 20262,804$3,140+2,804
ROTHSCHILD INVESTMENT LLCunchanged · filed 6 Aug 20262$200.0%
TD Waterhouse Canada Inc.new · filed 27 Jul 20262$2+2
DANSKE BANK A/Snew · filed 10 Aug 20261$1+1
30 Jun 2025 – 30 Jun 2026
8910Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Connie Matsui Company insiderDirector · last 17 Jul 20261 · 0
Douglas Blayney Company insiderDirector · last 17 Jul 20260 · 0
Gregory Reyes Company insiderDirector · last 17 Jul 20260 · 0
Robert Martin Emanuele Company insiderDirector · last 17 Jul 20260 · 0
Steven Kelly Company insiderDirector · last 17 Jul 20260 · 0
Tamara A. Favorito Company insiderDirector · last 17 Jul 20260 · 0
Gregory D. Gorgas Company insiderPres, CEO, CFO, Treas & Secr · last 29 Jan 202611 · 0
Mark Edward Spring Company insiderChief Financial Officer · last 29 Jan 20260 · 0
John W. Beck Company insiderDirector · last 16 Jul 20210 · 0
Peter Michael O'Brien Company insider10% owner · last 4 Sep 20190 · 0
Georgia Erbez Company insiderDirector · last 29 Aug 20190 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Interest coverFY 2025 · to 31 Dec 2025-58.78×
Share count trendFY 2025 · to 20 Feb 20265.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$600K

Analyst forecasts

No analyst forecasts yet.